FDA Drug Recalls

Recalls / Class III

Class IIID-1072-2019

Product

Clindamycin Injection, USP, 900 mg/6 mL (150 mg/mL), 6 mL vial, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA. NDC 47781-621-94

Affected lot / code info
Lot #: T96398, Exp.07/2019, T97492, Exp.04/2019, W28567, Exp. 09/2019, W31813, Exp.10/2019

Why it was recalled

Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Recalling firm

Firm
Pfizer Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
235 E 42nd St, N/A, New York, New York 10017-5703

Distribution

Quantity
8,320 cartons (25 vials per carton)
Distribution pattern
Nationwide USA and Guam

Timeline

Recall initiated
2019-03-15
FDA classified
2019-03-29
Posted by FDA
2019-04-10
Terminated
2022-08-11
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1072-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: drug · FDA Drug Recalls